Aug 31, 2022 11:55am EDT Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose
Aug 31, 2022 8:05am EDT Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline
Aug 23, 2022 8:05am EDT Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103
Aug 17, 2022 8:01am EDT Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call
Aug 11, 2022 4:10pm EDT Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results
Aug 09, 2022 4:20pm EDT Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing
Jul 27, 2022 8:05am EDT Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call
Jul 13, 2022 4:05pm EDT Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study